NeuroBo Pharmaceuticals Inc NRBO

NAS: NRBO | ISIN: US64132R1077   31/05/2024
3,810 USD (-6,16%)
(-6,16%)   31/05/2024

22 mei 2024 · NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone · Persbericht

9 mei 2024 · NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

30 april 2024 · NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June · Persbericht

17 april 2024 · NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity · Persbericht

1 april 2024 · NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH · Persbericht

28 maart 2024 · NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update · Persbericht

13 maart 2024 · NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH · Persbericht

4 maart 2024 · NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer · Persbericht

29 februari 2024 · NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity · Persbericht

12 februari 2024 · NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference · Persbericht

1 februari 2024 · NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity · Persbericht

18 januari 2024 · NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH · Persbericht

9 januari 2024 · NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement · Persbericht

2 januari 2024 · NeuroBo to Participate in Industry and Investor Conferences in January · Persbericht

28 december 2023 · NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity · Persbericht

19 december 2023 · NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split · Persbericht

1 december 2023 · NeuroBo to Participate in Investor Conferences in December · Persbericht

6 november 2023 · NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D. · Persbericht

17 oktober 2023 · NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference · Persbericht

15 september 2023 · NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH · Persbericht

Mijn selecties